Dermatologists call for delay in proposed Part B drug payment regs
Dermatologists are calling on the Centers for Medicare & Medicaid Services to delay implementation of the proposed regulations that will test new payment methods for Medicare Part B drugs.
CMS’s proposed rule is aimed at addressing the rising cost of drugs by targeting how doctors are... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 16, 2016 Category: Dermatology Source Type: news
8 steps to avoid legal risks from your practice website
CHICAGO – An inadequately designed medical practice website can pose serious legal dangers, said Michael J. Sacopulos, a medical malpractice defense attorney based in Terre Haute, Ind.
Here is a list of website to-dos that... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 16, 2016 Category: Dermatology Source Type: news
Study: TNF inhibitors improve extraintestinal IBD manifestations
SAN DIEGO – Tumor necrosis factor inhibitors improved the extraintestinal manifestations of inflammatory bowel disease (IBD) among more than half of affected patients, according to a national cohort study.
“The best response rates were for psoriasis, aphthous stomatitis, uveitis, and peripheral... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 15, 2016 Category: Dermatology Source Type: news
TB still a risk in psoriasis patients taking TNF blockers
Despite following guidelines aimed at reducing the likelihood of tuberculosis infection in patients with psoriasis treated with tumor necrosis factor antagonists, a French study has identified a number of active TB cases in this patient group.
The nationwide retrospective study identified 12 cases... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 15, 2016 Category: Dermatology Source Type: news
TNF blocker safety may differ in RA and psoriasis patients
Rheumatoid arthritis patients on anti–tumor necrosis factor medications had approximately twice the rate of serious adverse events as did psoriasis patients on the same medications, based on data from a pair of prospective studies of about 4,000 adults.
The findings were published online in the... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 14, 2016 Category: Dermatology Source Type: news
Full resolution of psoriasis in half of ixekizumab patients
More than half of the patients treated with the interleukin-17A antagonist, ixekizumab, achieved full resolution of skin plaques after a year of 2- to 4-week dosing, according to the latest analysis of data from the three UNCOVER trials of almost 4,000 patients with moderate to severe... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 14, 2016 Category: Dermatology Source Type: news
VIDEO: Smart insole system helped reduce reulceration risk
NEW ORLEANS – Patients with diabetes and peripheral neuropathy who used a smart watch and specially designed smart insoles equipped with an alert system minimized their reulceration risk, results from a proof-of-concept study demonstrated.
The findings suggest that mobile health “could be an... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 11, 2016 Category: Dermatology Source Type: news
Smart insole system helped reduce reulceration risk
NEW ORLEANS – Patients with diabetes and peripheral neuropathy who used a smart watch and specially designed smart insoles equipped with an alert system minimized their reulceration risk, results from a proof-of-concept study demonstrated.
The findings suggest that mobile health “could be an... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 11, 2016 Category: Dermatology Source Type: news
Prepare early for peer review hearings to avoid negative outcomes
CHICAGO – Being targeted for a peer review can be unnerving for physicians, but proper preparation can help doctors smoothly navigate the process and increase their chances for a favorable outcome.
The first step is taking the situation seriously and remaining calm, said <a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 10, 2016 Category: Dermatology Source Type: news
Adding calcipotriene to 5-FU dramatically reduced AKs
SCOTTSDALE, ARIZ. – A four-day topical combination regimen of 5-fluorouracil (5-FU) and calcipotriene removed almost 90% of facial actinic keratoses – significantly more than with 5-FU monotherapy, in a randomized, double-blind controlled study.
Calcipotriene (<a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 9, 2016 Category: Dermatology Source Type: news
Decision Support in Medicine: Pruritus
1. Are You Confident of the Diagnosis?Pruritus can be best defined as a sensation that leads to the desire to scratch. It is important to make a distinction between chronic and acute pruritus. All humans experience the acute form for a limited amount of time during the course of... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 8, 2016 Category: Dermatology Source Type: news
Keys to alopecia areata might lie in gut microbiome
SCOTTSDALE, ARIZ. – Wiping out the gut microbiome with antibiotics prevented alopecia areata in a study of mice, providing evidence that the gut microbiome may play a role in alopecia, Dr. James Chen reported at the annual meeting of the Society for Investigative Dermatology.
The finding shows... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 8, 2016 Category: Dermatology Source Type: news
JAK inhibitor improves alopecia, with caveats
SCOTTSDALE, ARIZ. – The Janus kinase (JAK) inhibitor tofacitinib dramatically improved several cases of alopecia areata (AA), although some patients relapsed to worse than baseline after completing treatment in a small open label pilot trial.
“Regrowth was demonstrated in 11 out of 12 patients on... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 8, 2016 Category: Dermatology Source Type: news
USPSTF updates recommendations for syphilis screening
Because syphilis infection rates have increased over the last decade, health care providers should screen patients for the disease more frequently to detect and treat it earlier and more effectively, particular in high-risk subgroups.
The <a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 7, 2016 Category: Dermatology Source Type: news
Déjà vu: An FDA warning about oral ketoconazole ... again
The Food and Drug Administration issued a health warning on May 16th, 2016, regarding the use of oral ketoconazole for the treatment of skin and nail dermatophyte and candidal infections – wait what? Why is this even an active discussion? Let’s take a step back: In July 2013, the FDA strengthened... (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 3, 2016 Category: Dermatology Source Type: news
